What does Korro Bio, Inc. do?
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It…
What is Korro Bio, Inc.'s P/E and P/B ratio?
Korro Bio, Inc. has a P/E ratio of -1.2 and a P/B ratio of 1.72.
What is Korro Bio, Inc.'s debt-to-equity ratio?
Korro Bio, Inc. has a debt-to-equity ratio of 0.41.
How much does Korro Bio, Inc. owe compared with what it owns?
Korro Bio, Inc. owes $0.37 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Korro Bio, Inc.'s Positivity rank?
Korro Bio, Inc. is ranked #2,575 of 6,774 companies globally and #861 of 4,000 in United States on PositoAI, with a Positivity Score of 21,362.
Does Korro Bio, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Korro Bio, Inc..
Where can I read the latest news about Korro Bio, Inc.?
Recent headlines about Korro Bio, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Korro Bio, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Korro Bio, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.